^
Association details:
| Biomarker: | FGFR3 mutation |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Padcev (enfortumab vedotin-ejfv) (Microtubule inhibitor, Nectin-4-targeted antibody-drug conjugate) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Enfortumab vedotin in FGFR3-mutated advanced urothelial carcinoma.
Published date:
02/08/2021
Excerpt:
89 patients received EV on completed monotherapy...Compared to FGFR3- pts, FGFR3+ pts with no prior FGFRi had significantly shorter median PFS on EV (2.5 vs. 6.8 months; HR 0.33 [0.14 – 0.80] p < .01) and trend towards shorter median OS (4.9 vs. 14.6 months; HR 0.42 [0.16 – 1.08] p > .05)...In this retrospective study, FGFR+ patients who receive EV first appear to have shorter PFS and lower ORR than those who have received prior FGFRi.
DOI:
10.1200/JCO.2021.39.6_suppl.458
